TY - JOUR
T1 - The role of pemetrexed in recurrent epithelial ovarian cancer
T2 - A scoping review
AU - Roche, Michael
AU - Parisi, Laura
AU - Li, Linda
AU - Knehans, Amy
AU - Phaeton, Rebecca
AU - Kesterson, Joshua P.
N1 - Publisher Copyright:
© CopyrightM. Roche et al, 2018.
PY - 2018/1/30
Y1 - 2018/1/30
N2 - Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (AlimtaT M) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current lit¬ erature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.
AB - Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (AlimtaT M) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current lit¬ erature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.
UR - http://www.scopus.com/inward/record.url?scp=85049181480&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049181480&partnerID=8YFLogxK
U2 - 10.4081/oncol.2018.346
DO - 10.4081/oncol.2018.346
M3 - Review article
C2 - 29983902
AN - SCOPUS:85049181480
SN - 1970-5557
VL - 12
SP - 8
EP - 13
JO - Oncology Reviews
JF - Oncology Reviews
IS - 1
ER -